Indivior Pharmaceuticals Inc
- Open
- 38.50
- Day high
- 39.15
- Day low
- 37.85
- Prev close
- 38.43
- Volume
- 2.3M
- Mkt cap
- $4.5B
- P/E (TTM)
- 13.5
- EPS (TTM)
- $2.87
- P/B
- -21.7
- P/S
- 3.4
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$2.8M over the last 3 months (1 open-market buy, 3 sales)
- 🏛Institutions accumulating (13F)
Indivior Pharmaceuticals Inc (INDV) is a Healthcare company listed on NASDAQ. The stock is up 70% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 3 sales (SEC Form 4).
Indivior Pharmaceuticals Inc (INDV) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
INDV earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 3, 2026 | $0.87 | $1.15 | +32.3% | $343M | +12.0% |
| Apr 30, 2026 | $0.64 | $0.96 | +50.0% | $317M | +16.2% |
| Oct 30, 2025 | $0.38 | $0.72 | +89.5% | $314M | +2.5% |
| Jul 31, 2025 | $0.26 | $0.51 | +96.2% | $302M | +18.3% |
| Apr 24, 2025 | $0.22 | $0.41 | +86.4% | $266M | +9.8% |
| Feb 20, 2025 | $0.32 | $0.32 | +0.0% | $299M | +24.5% |
| Oct 24, 2024 | $0.31 | $0.54 | +74.2% | $307M | +17.9% |
| Jul 25, 2024 | $0.40 | $0.44 | +10.0% | $300M | +3.5% |
| Apr 25, 2024 | $0.42 | $0.37 | -11.9% | $283M | -5.7% |
| Feb 22, 2024 | $0.28 | $0.43 | +53.6% | $301M | +8.9% |
| Nov 9, 2023 | $0.30 | $0.34 | +13.3% | $261M | -3.4% |
| Jul 27, 2023 | $0.22 | $0.39 | +77.3% | $280M | +9.7% |
INDV insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 5, 2026 | Anderson Woodrow Dofficer: Chief Accounting Officer | Buy | 1,500 | $36.28 |
| Jul 13, 2026 | Heidbreder Christianofficer: Chief Scientific Officer | Sell | 18,586 | $41.14 |
| Jun 23, 2026 | Ciaffoni Josephdirector, officer: Chief Executive Officer | Tax | 612,549 | $38.32 |
| Jun 23, 2026 | Ciaffoni Josephdirector, officer: Chief Executive Officer | Option | 1,266,903 | — |
| Jun 12, 2026 | Heidbreder Christianofficer: Chief Scientific Officer | Sell | 18,586 | $38.06 |
| Jun 10, 2026 | Preblick Ryanofficer: Chief Financial Officer | Sell | 36,000 | $37.70 |
| May 14, 2026 | Humphreys Keithdirector | Grant | 6,518 | — |
| May 14, 2026 | Thompson Julietdirector | Tax | 1,117 | $38.28 |
| May 14, 2026 | Thompson Julietdirector | Grant | 6,518 | — |
| May 14, 2026 | Wheadon David E.director | Grant | 10,430 | — |
| May 14, 2026 | Stejbach Markdirector | Grant | 6,518 | — |
| May 14, 2026 | Ryan Barbaradirector | Grant | 6,518 | — |
| May 14, 2026 | NINIVAGGI DANIEL Adirector | Grant | 6,518 | — |
| May 14, 2026 | Kingsley Stuart Adirector | Grant | 6,518 | — |
| Mar 17, 2026 | Preblick Ryanofficer: Chief Financial Officer | Option | 6,302 | — |
Source: INDV SEC Form 4 filings, latest Aug 5, 2026. For informational purposes only — not investment advice.
See the full INDV insider & 13F page →Indivior Pharmaceuticals Inc company profile
Overview
Indivior PLC (NASDAQ:INDV) is a specialty pharmaceutical company founded in 2014 through a spin-off from Reckitt Benckiser Group. Headquartered in North Chesterfield, Virginia, the company focuses exclusively on developing and commercializing treatments for substance use disorders, particularly opioid use disorder (OUD). Since its inception, Indivior has evolved from a diversified pharmaceutical company into a specialized addiction treatment provider, divesting non-core assets to concentrate on addressing the ongoing opioid crisis through innovative medication-assisted treatment solutions.
Business
Indivior operates in the specialty pharmaceutical sector, specifically targeting substance use disorders - a medical field focused on treating addiction to drugs, alcohol, and other substances. The company's core business revolves around medications that help patients overcome opioid addiction, a critical public health issue affecting millions globally. The company's flagship product is SUBLOCADE, a monthly injectable form of buprenorphine that provides sustained medication levels for treating opioid use disorder. Unlike daily oral medications, this long-acting injection eliminates the need for daily dosing and reduces the risk of diversion or misuse. SUBLOCADE represents approximately 64% of total revenue and serves as the primary growth driver. Indivior also markets SUBOXONE products (both sublingual films and tablets), which combine buprenorphine with naloxone for opioid addiction treatment. These products face significant generic competition and represent a declining revenue segment. The company's OPVEE nasal spray treats opioid overdose emergencies, particularly those involving synthetic opioids like fentanyl. Additional products include SUBUTEX (buprenorphine tablets) and PERSERIS (an injectable antipsychotic for schizophrenia, though the company discontinued active marketing of this product). The company maintains a development pipeline focusing on next-generation treatments for opioid, alcohol, and cannabis use disorders, including longer-acting formulations and novel mechanisms of action.
Revenue model
Indivior generates revenue primarily through product sales to healthcare providers, pharmacies, and institutional customers. The company operates a traditional pharmaceutical business model where it develops, manufactures, and sells prescription medications through established distribution channels. Revenue streams break down as follows: SUBLOCADE accounts for approximately 64% of total revenue (~$756 million in 2024), SUBOXONE products contribute roughly 25-30%, and other products including OPVEE represent the remainder. The company sells to three main customer segments: retail pharmacies serving individual patients, organized health systems including hospitals and clinics, and criminal justice facilities providing treatment to incarcerated individuals. Several factors significantly impact Indivior's margins and profitability. Positive margin drivers include the premium pricing of SUBLOCADE due to its unique monthly injection format, growing patient volumes as opioid treatment penetration increases, and cost reduction initiatives that have generated over $100 million in annual savings. The company benefits from limited direct competition for long-acting injectable buprenorphine treatments. Negative margin pressures stem from intense generic competition eroding SUBOXONE revenues, funding constraints in criminal justice systems that limit institutional purchases, and ongoing litigation costs related to opioid-related lawsuits. Additionally, the company faces pricing pressure from pharmacy benefit managers and potential competition from Camurus's BRIXADI, another monthly injectable competing directly with SUBLOCADE. Regulatory changes affecting Medicaid reimbursement and shifts in treatment protocols also pose margin risks.
Competitive moat
Indivior possesses a moderate competitive moat built primarily around its specialized expertise in addiction medicine and regulatory barriers, though this moat faces increasing pressure from competition and market dynamics. The company's strongest defensive position lies in SUBLOCADE's clinical differentiation. As a monthly injection, it offers unique therapeutic advantages over daily oral medications, including improved patient compliance, reduced diversion risk, and sustained drug levels. This creates switching costs for both patients and healthcare providers who have established treatment protocols around the product. Regulatory expertise represents another moat element, as developing addiction treatments requires navigating complex FDA approval processes and demonstrating safety in vulnerable patient populations. Indivior's decade-plus experience in this specialized field creates barriers for new entrants unfamiliar with addiction medicine regulatory pathways. However, the moat shows clear vulnerabilities. Direct competition from Camurus's BRIXADI, another monthly buprenorphine injection, has captured approximately 30% of new patient starts, demonstrating that clinical differentiation alone provides limited protection. Generic competition has devastated SUBOXONE revenues, showing how patent expiration eliminates pricing power. The company lacks significant intellectual property protection for its core products going forward, and the addiction treatment market remains relatively small and specialized, limiting the economic moats available. Additionally, pricing pressure from payers and funding constraints in key customer segments like criminal justice systems suggest weak pricing power. Overall, while Indivior maintains competitive advantages in the near term, these appear insufficient to provide durable long-term protection against determined competitors.
Risks & safety
Indivior presents moderate financial risk with concerning debt levels but adequate liquidity for near-term operations. **Liquidity and Solvency:** - Cash position: $372 million as of Q1 2025 - Current ratio: 0.88 (below 1.0 indicates potential liquidity concerns) - Total debt significantly exceeds equity, with debt-to-equity ratio of -1.29 - Free cash flow: $70 million in Q1 2025, showing positive cash generation **Debt and Obligations:** - Total liabilities: $1.66 billion versus total assets of $1.38 billion - Negative book value of approximately $286 million - Significant litigation settlements and ongoing legal obligations - Management confident in meeting known obligations through early 2027 **Valuation Metrics:** - Price-to-earnings ratio: 6.3x (appears reasonable) - EV/EBITDA: 3.9x (attractive for a specialty pharma) - Price-to-book: Not meaningful due to negative book value **Other Considerations:** - Revenue concentration risk with SUBLOCADE representing 64% of sales - Declining SUBOXONE revenues creating transition period challenges - Regulatory dependency for key product approvals and label expansions
Recent development
Over the past few years, Indivior has undergone a significant strategic transformation from a diversified pharmaceutical company to a focused addiction treatment specialist. The company divested non-core assets, discontinued PERSERIS marketing, and streamlined operations to concentrate exclusively on substance use disorders. The most significant development has been the SUBLOCADE expansion strategy. Patient numbers have grown from 82,500 in 2022 to over 170,000 by 2025, representing more than doubling of the patient base. The company has successfully expanded into organized health systems and criminal justice facilities, with the latter now representing 20% of SUBLOCADE revenue. Management targets reaching 270,000 patients to achieve peak revenue of $1.5 billion. Pipeline rationalization has been another key strategic shift. The company discontinued several development programs including INDV-5004 for cannabinoid overdose, the AELIS cannabis use disorder collaboration, and INDV-1000 for alcohol use disorder. Resources have been concentrated on two core assets: INDV-6001 (a three-month buprenorphine injectable) and INDV-2000 (an orexin-1 receptor antagonist for opioid use disorder). The OPVEE acquisition through the Opiant Pharmaceuticals purchase represents an attempt to diversify into overdose reversal treatments. However, commercial progress has been limited due to pushback from harm reduction advocates, and the company is focusing on evidence generation rather than aggressive commercialization. Operational efficiency improvements have generated over $100 million in annual cost savings, which the company is partially reinvesting into SUBLOCADE marketing and development programs. The company has also completed a primary U.S. listing transition and will begin reporting under U.S. GAAP, reflecting its strategic focus on the American market.
INDV company profile · for informational purposes only — not investment advice.
Track INDV with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free